Twitter

Archive for August 8th, 2012


Trial Suggests New Treatment Option for Some Women with Metastatic Breast Cancer

Results from a phase III clinical trial suggest that, for some women with metastatic breast cancer, combining two drugs that work in different ways to disrupt estrogen’s ability to fuel cancer growth may delay disease progression and death.

Read More...

Single HPV Test Predicts the Risk of Cervical Cancer for 18 Years

In a group of more than 20,000 women, the human papillomavirus (HPV) DNA test more accurately predicted the risk of developing cervical cancer over an 18-year follow-up period than the Pap test. Although both tests could identify women who were most likely to develop high-grade precancerous cervical lesions or squamous cervical cancers within 2 years of testing, only the HPV test result predicted the risk for women up to 18 years later.

Read More...

New Research Tool Estimates Risk of Radiation-Related Cancers

NCI has released the first online radiation risk assessment tool, RadRAT, for use by researchers. The tool can be used for estimating an individual’s lifetime risk of radiation-related cancers.

Read More...

Prostate cancer survivor touts proton therapy

Just eight years ago — 10 days after the birth of his first child — Stewart Taylor was diagnosed with prostate cancer. KOCO Eyewitness News 5′s Rachel Calderon has his story.

Read More...

Gemcitabine in NK/T Cell Lymphoma

Conditions :   Efficacy;   Gemciatbine;   Refractory or Relapsed NK/T Cell Lymphoma Intervention :   Sponsors :   Samsung Medical Center;   Samsung Medical Center Recruiting – verified August 2012

Read More...

Radiation Induced Cystits Treated With Hyperbaric Oxygen – A Randomized Controlled Trial

Condition :   Cystitis, Radio Induced Intervention :   Drug: Hyperbaric Oxygen Sponsors :   Göteborg University;   Göteborg University;   Sahlgrenska University Hospital, Sweden Recruiting – verified August 2012

Read More...

Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast

Condition :   Breast Cancer Intervention :   Drug: FACBC radiotracer Sponsors :   Emory University;   Emory University Recruiting – verified August 2012

Read More...

BMS-247550 in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma

Condition :   Lymphoma Intervention :   Drug: ixabepilone Sponsors :   National Cancer Institute (NCI);   University of Chicago;   National Cancer Institute (NCI) Completed – verified October 2007

Read More...

Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell

Conditions :   Myeloid Leukemia, Chronic;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes (MDS);   Lymphoma, Non-Hodgkin Intervention :   Biological: Conventional T cells (Tcon) and Regulatory T cells (Treg) Sponsors :   Stanford University;   Ginna Laport;   National Institutes of Health (NIH) Recruiting – verified August 2012

Read More...

Phase II Phosphatidylinositol 3-Kinase (PI3K) Inhibitor in Relapsed, Indolent or Aggressive Non-Hodgkin’s Lymphomas (NHL)

Condition :   Lymphoma, Non-Hodgkin Intervention :   Drug: BAY80-6946 Sponsors :   Bayer;   Bayer Not yet recruiting – verified August 2012

Read More...